Aventis Pharma: Margins slide - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Aventis Pharma: Margins slide

Jul 31, 2002

Aventis Pharma, has reported a strong topline growth for 1HFY03 on the back of strong performance of its strategic brands and jump in exports to CIS countries. The results for the relevant period under review are on a merged basis with RPR (Rhone Poulenc Rorer) and hence not exactly comparable on a like to like basis.

(Rs m)2QFY022QFY03% Change1HFY021HFY03% Change
Net Sales 1,212 1,577 30.1% 2,390 2,924 22.3%
Other Income 13 17 30.8% 55 41 -25.5%
Expenditure 969 1,317 35.9% 1,956 2,482 26.9%
Operating Profit (EBDIT) 243 260 7.0% 434 442 1.8%
Operating Profit Margin (%)20.0%16.5% 18.2%15.1%
Interest 4 1 -75.0% 11 3 -72.7%
Depreciation 37 37 0.0% 75 74 -1.3%
Profit before Tax 215 239 11.2% 403 406 0.7%
Extraordinary Expenses (VRS) (40) 18 -145.0% 70 1 -98.6%
Tax 53 87 64.2% 149 130 -12.8%
Profit after Tax/(Loss) 122 170 39.3% 324 277 -14.5%
Net profit margin (%)10.1%10.8% 13.6%9.5% 
No. of Shares (eoy) (m) 23 23   23 23  
Diluted Earnings per share*21.229.6 28.224.1 
P/E (at current price)  13.0    16.0  
(*- annualised)      

Domestic sales have grown 22% from Rs 1.1 bn to Rs 1.3 bn including Rs 84 m from merger of RPR business. The performance has been on the back of strong growth in strategic products such as cardace (42% - cardiovascular), Allegra (24% - allergy), Amaryl (49% - anti-diabetes) and Targocid (40% - anti-infective). Formulations exports sales (mainly to CIS countries) have recorded a growth of more than 68%. However, the management has stated that this exports growth rate is unsustaintable going forward.

Despite strong sales growth, operating margins have been playing a spoil sport. Operating margins dropped from 18.2% in 1HFY02 to 15.1%. Though the company's products enjoy a strong brand equity, it faces stiff competition from generic products. Raw material consumption to sales ratio indicates a drop in realisations for the company's products. Further, operating margins have also been affected on account of front loading of marketing expenses for products (Lantus and Actonel) expected to be launched in the next year. The company has stated that they expect these product promotion expenses to decline in the coming quarters.

At the current market price of Rs 385, the stock trades at 12x our expected earnings for FY03. On the back of the support extended by the parent, Aventis has transformed itself from a company catering mainly to the anti-infectives and pain management segments to a company with a strong and focused portfolio of products for the chronic and critical-care therapeutic segments. The strategic brands continue to grow at healthy growth rates and this is expected to offset the impact of the laggards in its folio. This portfolio bias is expected to continue in the foreseeable future as well. Notwithstanding some unclarity on the impact of the DPCO order, valuations of the company are attractive on a peer comparision basis.

Equitymaster requests your view! Post a comment on "Aventis Pharma: Margins slide". Click here!

  

More Views on News

SANOFI INDIA Announces Quarterly Results (2QFY21); Net Profit Up 5.0% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY21); Net Profit Up 39.9% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Points to Keep in Mind Before Subscribing to Krishna Institute of Medical Sciences' IPO (Views On News)

Jun 15, 2021

All you need to know about the IPO of Krishna Institute of Medical Sciences.

Why Did Shares of Divi's Lab Rally Today? (Views On News)

Jun 10, 2021

The stock jumped 3.6% in intraday trade to hit its 52-week high.

Laurus Labs Hits New Life High. Up 500%+ in One Year (Views On News)

Jun 8, 2021

Laurus Labs trades higher for the eight straight day, soars 73% in 3 months.

More Views on News

Most Popular

Hotel Stocks Will Reward Investors (Fast Profits Daily)

Jun 8, 2021

This is why I'm bullish on the hotel and hospitality sector.

My 'Unlock' Investments (Fast Profits Daily)

Jun 11, 2021

The best unlock investments you can make in the market.

The Most Visible Sign of India's Revival is on Two Wheels (Profit Hunter)

Jun 9, 2021

Investing in the best stocks could result in wealth compounding on a massive scale.

How I Discovered a 400-Year-Old Open Secret to Extreme Wealth (Profit Hunter)

Jun 11, 2021

Charlie Munger's open secret about investing success.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Jun 18, 2021 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS